Integrin Alpha 4 - Pipeline Review, H2 2019
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 3, 4 and 3 respectively.
Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Ophthalmology, Cardiovascular, Genetic Disorders, Musculoskeletal Disorders and Respiratory which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Multiple Sclerosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma, Bone Fracture, Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Keratoconjunctivitis Sicca (Dry Eye), Osteonecrosis, Osteoporosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Rheumatoid Arthritis, Secondary Progressive Multiple Sclerosis (SPMS) and Ventricular Septal Defect.
Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook